dKIF976 / Accutar Biotech - LARVOL DELTA

A first-in-class KIF11 degrader antibody conjugate (DAC) as a potential therapy targeting a broad spectrum of cancers. (ASCO 2025) - "dKIF976 achieves specific and potent KIF11 degradation, inducing mitotic arrest and robust cancer cell growth inhibition. Its superior efficacy and unique mechanism of action establish it as a highly promising payload for antibody conjugates. dKIF976 DACs demonstrated strong antigen-dependent KIF11 degradation and cell growth inhibition."

Oncology • Targeted Protein Degradation • CRBN • KIF11